Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00430846 | Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies | completed | Phase 1 | 45 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00649584 | A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies | terminated | Phase 1 | 44 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00655837 |
| Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL |
| completed |
| Phase 1 |
| 33 |
| Seagen Inc.INDUSTRY |
| 1 |
| Dec 18, 2014 |
| clinicaltrials |
| NCT01015911 | A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma | completed | Phase 1 | 58 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01026415 | Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | completed | Phase 1 | 73 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01060904 | A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | completed | Phase 1 | 51 | Seagen Inc.INDUSTRY | 2 | Dec 18, 2014 | clinicaltrials |
| NCT01026233 | Cardiac Safety Study of Brentuximab Vedotin (SGN-35) | completed | Phase 1 | 52 | Seagen Inc.INDUSTRY | 2 | Dec 12, 2014 | clinicaltrials |
| NCT00968656 | Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1(FISO PET/CT) | completed | Phase 1 | 31 | Washington University School of MedicineOTHER | 1 | Dec 9, 2014 | clinicaltrials |
| NCT01561911 | A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment | completed | Phase 1 | 29 | Cancer Research UKOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT00991562 | IMGN901 in Combination With Lenalidomide and Dexamethasone | completed | Phase 1 | 50 | ImmunoGen, Inc.INDUSTRY | 1 | Nov 21, 2014 | clinicaltrials |
| NCT01158274 | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 2 | Nov 7, 2014 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 | clinicaltrials |
| NCT00891137 | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | completed | Phase 1 | 30 | Cellerant TherapeuticsINDUSTRY | 1 | Oct 27, 2014 | clinicaltrials |
| NCT00070616 | Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support | completed | Phase 1 | 25 | Swedish Orphan BiovitrumINDUSTRY | 0 | Oct 24, 2014 | clinicaltrials |
| NCT02274584 | CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) | unknown | Phase 1 / Phase 2 | 20 | Peking UniversityOTHER | 2 | Oct 24, 2014 | clinicaltrials |
| NCT02247609 | Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas(4SCAR19273) | unknown | Phase 1 / Phase 2 | 20 | Peking UniversityOTHER | 1 | Oct 20, 2014 | clinicaltrials |
| NCT00349596 | A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) | completed | Phase 1 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT00525447 | Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 | 36 | Seagen Inc.INDUSTRY | 1 | Oct 9, 2014 | clinicaltrials |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2014 | clinicaltrials |
| NCT02248402 | Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma(Vax-DC/MM) | unknown | Phase 1 / Phase 2 | 15 | Chonnam National University HospitalOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT00675428 | Study of Natalizumab in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | BiogenINDUSTRY | 1 | Sep 19, 2014 | clinicaltrials |
| NCT01504776 | Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)(BUS48T) | completed | Phase 1 | 3 | Anand JillellaOTHER | 1 | Sep 19, 2014 | clinicaltrials |
| NCT00964873 | A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia | completed | Phase 1 | 29 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Sep 18, 2014 | clinicaltrials |
| NCT00004258 | EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer | completed | Phase 1 | 40 | Indiana UniversityOTHER | 1 | Sep 17, 2014 | clinicaltrials |
| NCT00477945 | Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL | completed | Phase 1 | 18 | Indiana UniversityOTHER | 1 | Sep 11, 2014 | clinicaltrials |
| NCT01435720 | Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) | unknown | Phase 1 / Phase 2 | 15 | Senesco Technologies, Inc.INDUSTRY | 2 | Sep 11, 2014 | clinicaltrials |
| NCT01538472 | Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2014 | clinicaltrials |
| NCT00003107 | Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors | completed | Phase 1 | — | Indiana UniversityOTHER | 1 | Sep 10, 2014 | clinicaltrials |
| NCT00787527 | SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 9, 2014 | clinicaltrials |
| NCT01689220 | A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea | completed | Phase 1 | 6 | Solasia Pharma K.K.INDUSTRY | 1 | Sep 4, 2014 | clinicaltrials |
| NCT02117336 | Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | suspended | Phase 1 | 36 | Piramal Enterprises LimitedINDUSTRY | 1 | Sep 3, 2014 | clinicaltrials |
| NCT00275080 | Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2014 | clinicaltrials |
| NCT02115035 | A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib | withdrawn | Phase 1 / Phase 2 | 0 | University of ArkansasOTHER | 1 | Aug 27, 2014 | clinicaltrials |
| NCT02095574 | A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma | withdrawn | Phase 1 | 0 | AbbVieINDUSTRY | 0 | Aug 13, 2014 | clinicaltrials |
| NCT00729638 | RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 28 | Massachusetts General HospitalOTHER | 1 | Aug 11, 2014 | clinicaltrials |
| NCT00458744 | Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment | withdrawn | Phase 1 | 0 | Children's Oncology GroupNETWORK | 0 | Aug 8, 2014 | clinicaltrials |
| NCT00110071 | Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 | 38 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 6, 2014 | clinicaltrials |
| NCT00621452 | Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 6, 2014 | clinicaltrials |
| NCT00185965 | CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas | completed | Phase 1 / Phase 2 | 30 | Ronald LevyOTHER | 1 | Aug 1, 2014 | clinicaltrials |
| NCT02206308 | Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma. | completed | Phase 1 | 15 | Sinocelltech Ltd.INDUSTRY | 0 | Aug 1, 2014 | clinicaltrials |
| NCT01032681 | EMD 521873 in Advanced Solid Tumors, MTD Finding | completed | Phase 1 | 66 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 2 | Jul 31, 2014 | clinicaltrials |
| NCT00003217 | Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | completed | Phase 1 | 20 | Children's Oncology GroupNETWORK | 2 | Jul 25, 2014 | clinicaltrials |
| NCT01292135 | Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 33 | Pharmacyclics LLC.INDUSTRY | 1 | Jul 24, 2014 | clinicaltrials |
| NCT01534949 | Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial(Triad-DLBCL) | terminated | Phase 1 | 1 | CelltrionINDUSTRY | 1 | Jul 23, 2014 | clinicaltrials |
| NCT02182141 | An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 17 | Boehringer IngelheimINDUSTRY | 0 | Jul 18, 2014 | clinicaltrials |
| NCT01132573 | Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2014 | clinicaltrials |
| NCT01279707 | Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)(MARALL) | unknown | Phase 1 / Phase 2 | 55 | Queen Mary University of LondonOTHER | 1 | Jul 14, 2014 | clinicaltrials |
| NCT01354392 | AZD1152 in Diffuse Large B-cell Lymphoma | completed | Phase 1 / Phase 2 | 15 | Oxford University Hospitals NHS TrustOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT00412321 | A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease | completed | Phase 1 | 67 | Centocor, Inc.INDUSTRY | 1 | Jul 1, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Dec 18, 2014source: clinicaltrials